United Kingdom

Disclosure of payments made to HCPs in the UK

As part of our goal to be one of the most innovative, best performing and trusted healthcare companies in the world, we seek to meet society’s evolving expectations, bring greater transparency to an already well-regulated industry, and strengthen our relationships with Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) future collaboration.

Cooperation between pharmaceutical companies, regulators, HCPs, HCOs, and patients, is essential for the sustainable improvement of healthcare. These relationships have helped deliver numerous innovative new medicines and changed the way many diseases impact on our lives. HCPs have always been, and will always be, valuable partners for GSK. As experts in their field, they provide us with first hand scientific and medical knowledge and unique insights into patient care. This partnership is fundamental to the progression of medical science, helping to meet patient and public health needs.

Under the EFPIA Disclosure Code, from 2016 EFPIA member companies pledged to disclose the transfers of value they make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes, for example, sponsorship for travel and registration fees to attend medical congresses, HCP consultancy fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.

Transfer of value disclosure information is published annually (covering the previous year) on a public platform; either the company’s own website or, in some countries, a central platform combining data from different companies.

In line with EFPIA Disclosure Code, disclosure information in the UK is published annually (covering the previous year) through the Association of the British Pharmaceutical Industry (ABPI) Disclosure UK website: www.disclosureuk.org.uk

Following the acquisition of TESARO in 2019, GSK has aligned with EFPIA guidance that in the case of a new entity (following M&A) transfer of value disclosure associated with the acquisition can be implemented with a 12-month delay, unless required by local regulation or local law. Therefore, all transfers of value incurred for TESARO activity in the UK in 2019 will be disclosed separately this year on the ABPI Disclosure UK website.

Our disclosures for the United Kingdom

The links below will take you to our disclosures for the UK in line with the EFPIA code and ABPI Disclosure UK data, and to a note on the methodology used to set out the data in the report.

Temporary changes to the publication of 2019 data on Disclosure UK in June 2020

The ABPI is making a temporary change to the way Disclosure UK data is published to minimise any pressure on the NHS during the COVID-19 pandemic. This means that some of the data will not be broken down as normal. This is a temporary change because of the unprecedented situation, and they remain committed to resuming the normal process as soon as the situation allows.

At GSK, we are committed to transparency in payments to healthcare professionals. As per the ABPI’s guidance, and due to the robust nature of our agreements, we can publish our full 2019 data without impacting on NHS time and resources. Our disaggregate data can be found below.

Year

Report

Methodological note

2019 PDF PDF

Previous years

Report

Methodological note

2018

See Disclosure UK

See Disclosure UK

2017

See Disclosure UK

See Disclosure UK

TESARO disclosure in the United Kingdom

Year

Report

Methodological note

2019 See Disclosure UK See Disclosure UK

Media enquiries: Please contact the UK Pharma Communications Team on +44 208 990 2144.